LERANA

QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substance: one film-coated tablet contains 2.5 mg of letrozole.

Excipients with known effect: contains lactose monohydrate

THERAPEUTIC INDICATIONS

Adjuvant treatment applied in postmenopausal women with early stage of breast cancer with positive hormone receptors.

Extended adjuvant treatment of breast cancer with positive hormone receptors in postmenopausal women who already done standard adjuvant treatment for five years of Tamoxifen.

First-line of treatment of advanced breast cancer with positive hormone receptors applied in postmenopausal women.

Treatment of advanced breast cancer applied in women with natural or artificially induced menopause after relapse or disease progression which has been treated with Antiestrogens.

Neoadjuvant treatment applied in postmenopausal women with HER-2 negative breast cancer with positive hormone receptors when the chemotherapy is not appropriate and when the immediate surgery is not indicated.

In patients with hormone receptor of negative breast cancer efficacy has not been demonstrated.

DISPENSING AND REIMBURSEMENT

Medicinal product is subjected to medical prescription. The medicinal product is covered by public health insurance.